Literature DB >> 22938804

Correction of contracture and recurrence rates of Dupuytren contracture following invasive treatment: the importance of clear definitions.

Paul M N Werker1, Gary M Pess, Annet L van Rijssen, Keith Denkler.   

Abstract

PURPOSE: To call attention to the wide variety of definitions for recurrence that have been employed in studies of different invasive procedures for the treatment of Dupuytren contracture and how this important limitation has contributed to the wide range of reported results.
METHODS: This study reviewed definitions and rates of contracture correction and recurrence in patients undergoing invasive treatment of Dupuytren contracture. A literature search was carried out in January 2011 using the terms "Dupuytren" AND ("fasciectomy" OR "fasciotomy" OR "dermofasciectomy" OR "aponeurotomy" OR "aponeurectomy") and limited to studies in English.
RESULTS: The search returned 218 studies, of which 21 had definitions, quantitative results for contracture correction and recurrence, and a sample size of at least 20 patients. Definitions for correction of contracture and recurrence varied greatly among articles and were almost always qualitative. Percentages of patients who achieved correction of contracture (ie, responder rate) when evaluated at various times after completion of surgery ranged from 15% to 96% for fasciectomy/aponeurectomy. Responder rates were not reported for fasciotomy/aponeurotomy. Recurrence rates ranged from 12% to 73% for patients treated with fasciectomy/aponeurectomy and from 33% to 100% for fasciotomy/aponeurotomy. Review of these reports underscored the difficulty involved in comparing correction of contracture and recurrence rates for different surgical interventions because of differences in definition and duration of follow-up.
CONCLUSIONS: Clearly defined objective definitions for correction of contracture and for recurrence are needed for more meaningful comparisons of results achieved with different surgical interventions. CLINICAL RELEVANCE: Recurrence after surgical intervention for Dupuytren contracture is common. This study, which evaluated reported rates of recurrence following surgical treatment of Dupuytren contracture, provides clinicians with practical information regarding expected long-term outcomes of surgical treatment choices. TYPE OF STUDY/LEVEL OF EVIDENCE: Economic and decision analysis III.
Copyright © 2012 American Society for Surgery of the Hand. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22938804     DOI: 10.1016/j.jhsa.2012.06.032

Source DB:  PubMed          Journal:  J Hand Surg Am        ISSN: 0363-5023            Impact factor:   2.230


  18 in total

1.  Factors influencing recurrence and progression of Dupuytren's disease treated by Collagenase Clostridium histolitycum.

Authors:  Clarisa Simón-Pérez; Julian Alía-Ortega; Belen García-Medrano; Jose Ignacio Rodríguez-Mateos; Maria Brotat-Rodríguez; Hector Aguado-Hernandez; Miguel Angel Martín-Ferrero
Journal:  Int Orthop       Date:  2017-11-23       Impact factor: 3.075

2.  Efficacy and safety of collagenase Clostridium histolyticum injection for Dupuytren contracture: report of 40 cases.

Authors:  F Alberton; M Corain; A Garofano; L Pangallo; A Valore; V Zanella; R Adani
Journal:  Musculoskelet Surg       Date:  2013-11-20

3.  Skin Graft Review in Dermofasciectomy for Dupuytren's Contracture within 48 Hours: Challenging Historical Practice.

Authors:  Saif Akhter Ansari; James Andrew Kennedy; Fizan Younis
Journal:  J Hand Microsurg       Date:  2021-03-23

Review 4.  Dupuytren's Disease-Etiology and Treatment.

Authors:  Mike Ruettermann; Robert Michael Hermann; Karl Khatib-Chahidi; Paul M N Werker
Journal:  Dtsch Arztebl Int       Date:  2021-11-19       Impact factor: 8.251

5.  Minimally invasive partial fasciectomy for Dupuytren's contractures.

Authors:  Scott Gelman; Robert Schlenker; Abdo Bachoura; Sidney M Jacoby; Jeffrey Lipman; Eon K Shin; Randall W Culp
Journal:  Hand (N Y)       Date:  2012-12

6.  Examining the efficacy and maintenance of contracture correction after collagenase clostridium histolyticum treatment for Dupuytren's disease.

Authors:  Heather A McMahon; Abdo Bachoura; Sidney M Jacoby; David S Zelouf; Randall W Culp; A Lee Osterman
Journal:  Hand (N Y)       Date:  2013-09

7.  Seven-year clinical outcomes after collagenase injection in patients with Dupuytren's disease: A prospective study.

Authors:  Rocco De Vitis; Marco Passiatore; Andrea Perna; Silvia Careri; Vitale Cilli; Giuseppe Taccardo
Journal:  J Orthop       Date:  2020-03-29

8.  Clinical Results of Percutaneous Needle Fasciotomy for Dupuytren's Disease in Japanese Patients.

Authors:  Yoshihiro Abe; Susumu Tokunaga
Journal:  Plast Reconstr Surg Glob Open       Date:  2015-06-05

Review 9.  Postapproval clinical experience in the treatment of Dupuytren's contracture with collagenase clostridium histolyticum (CCH): the first 1,000 days.

Authors:  Scott M Schulze; James P Tursi
Journal:  Hand (N Y)       Date:  2014-12

Review 10.  Surgery for Dupuytren's contracture of the fingers.

Authors:  Jeremy N Rodrigues; Giles W Becker; Cathy Ball; Weiya Zhang; Henk Giele; Jonathan Hobby; Anna L Pratt; Tim Davis
Journal:  Cochrane Database Syst Rev       Date:  2015-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.